The study set out to determine the levels of metalloproteinases MMP-1, MMP-3 and MMP-8, as well as tissue inhibitor TIMP-1 in patients with osteoarthritis, following the administration of anti-rheumatic agents. Here, MMP1 is linked to osteoarthritis.